Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 20/20 | 0.69 |
| ▸ | CRBN | Q96SW2 | 20/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29179837 | 0.90 | DDB1 (0.69) | DDB1CRBN | |
| SCHEMBL26329799 | 0.90 | DDB1 (0.68) | DDB1CRBN | |
| SCHEMBL29535454 | 0.90 | DDB1 (0.68) | DDB1CRBN | |
| SCHEMBL25027239 | 0.90 | DDB1 (0.68) | DDB1CRBN | |
| SCHEMBL26329796 | 0.90 | DDB1 (0.68) | DDB1CRBN | |
| SCHEMBL31376436 | 0.88 | CRBN (0.66) | DDB1CRBN | |
| SCHEMBL25023293 | 0.88 | CRBN (0.66) | DDB1CRBN | |
| SCHEMBL23538523 | 0.88 | DDB1 (0.63) | DDB1CRBN | |
| SCHEMBL29744807 | 0.88 | DDB1 (0.63) | DDB1CRBN | |
| SCHEMBL31451251 | 0.88 | DDB1 (0.68) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | DDB1 206/4885CRBN 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.